AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26237520 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cholecalciferol (daily 800 IU vitamin D3)
Number of subjects: 230
Study 26237520 — intervention group
Group type: COMPARATOR
Intervention: Placebo (daily white and twice monthly yellow placebo)
Number of subjects: 230
Study 26237520 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cholecalciferol
Number of subjects: 230
Study 26237520 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cholecalciferol
Number of subjects: 230
Study 26237520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study 23602388 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training
Number of subjects: 22
Study 21716250 — intervention group
Group type: COMPARATOR
Intervention: Phenobarbital (group 1, 34 patients)
Number of subjects: 96
Study 21716250 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (group 2, 31 patients)
Number of subjects: 96
Study 21716250 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (group 3, 31 patients)
Number of subjects: 96
Study 19598025 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedure for prolapse and hemorrhoids (PPH)
Number of subjects: 211
Study 19598025 — intervention group
Group type: COMPARATOR
Intervention: Milligan-Morgan hemorrhoidectomy (MM)
Number of subjects: 211
Study 16436824 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone scintigraphy with SPECT prior to injection (Group A1)
Number of subjects: 47
Study 16436824 — intervention group
Group type: COMPARATOR
Intervention: Facet joint injections at levels indicated by referring physician without bone scintigraphy (Group B)
Number of subjects: 47
Study 16436824 — intervention group
Group type: COMPARATOR
Intervention: Facet joint injections at levels decided as in group B (Group A2)
Number of subjects: 47
Study 15327411 — intervention group
Group type: COMPARATOR
Intervention: Adefovir dipivoxil (ADV) 10 mg daily
Number of subjects: 0
Study 15327411 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (ADV) 30 mg daily
Number of subjects: 0
Study 15327411 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11700777 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol therapy
Number of subjects: 0
Study 9315530 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban (10 microg/kg bolus over 3 minutes followed by 0.15 microg x kg(‐1) x min(‐1) infusion for 36 hours)
Number of subjects: 2139
Study 9315530 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 2139
Study 8328844 — intervention group
Group type: EXPERIMENTAL
Intervention: Autotransfusion for 12 hours after surgery
Number of subjects: 35
Study 8328844 — intervention group
Group type: COMPARATOR
Intervention: Standard chest drainage and fluid replacement (Control)
Number of subjects: 35
Study 3574819 — intervention group
Group type: EXPERIMENTAL
Intervention: Single preoperative dose of cefazolin
Number of subjects: 135
Study 3574819 — intervention group
Group type: COMPARATOR
Intervention: Three perioperative doses of cefazolin
Number of subjects: 135
Study 3574819 — intervention group
Group type: COMPARATOR
Intervention: Single dose of cefonicid
Number of subjects: 135
Study 29698927 — intervention group
Group type: EXPERIMENTAL
Intervention: trastuzumab plus capecitabine (HX)
Number of subjects: 86
Study 29698927 — intervention group
Group type: EXPERIMENTAL
Intervention: lapatinib plus capecitabine (LX)
Number of subjects: 86
Study 27279544 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib (60 mg once a day)
Number of subjects: 658
Study 27279544 — intervention group
Group type: COMPARATOR
Intervention: Everolimus (10 mg once a day)
Number of subjects: 658
Study 23567376 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth problem-solving therapy (tele-PST)
Number of subjects: 121
Study 23567376 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person problem-solving therapy (PST)
Number of subjects: 121
Study 23567376 — intervention group
Group type: COMPARATOR
Intervention: Telephone support calls
Number of subjects: 121
Study 23226893 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-education, case management, interpersonal psychotherapy and/or antidepressants by lay health workers
Number of subjects: 2181
Study 23226893 — intervention group
Group type: COMPARATOR
Intervention: Physician treatment
Number of subjects: 2181
Study 20012912 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume controlled low tidal volume ventilation plus medicated (saline + surfactant) BAL
Number of subjects: 44
Study 20012912 — intervention group
Group type: COMPARATOR
Intervention: Volume controlled low tidal volume ventilation (Control Group)
Number of subjects: 44
Study 18441037 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial casting
Number of subjects: 26
Study 18441037 — intervention group
Group type: COMPARATOR
Intervention: Positioning
Number of subjects: 26
Study 16036424 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole treatment
Number of subjects: 2069
Study 11885789 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracameral unpreserved lignocaine 1%
Number of subjects: 135
Study 11885789 — intervention group
Group type: COMPARATOR
Intervention: Placebo (balanced salt solution)
Number of subjects: 135
Study 10358675 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced tracking and follow-up services by community health workers
Number of subjects: 421
Study 10358675 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 421
Study 7547090 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenidap sodium (120 mg)
Number of subjects: 14
Study 7547090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 7547090 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenidap sodium
Number of subjects: 14
Study 2286595 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 400 mg once daily
Number of subjects: 102
Study 2286595 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin/clavulanic acid 500/125 mg three times daily
Number of subjects: 102
Study 7042361 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoprofen, 600 mg daily
Number of subjects: 44
Study 7042361 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA), 3 g daily
Number of subjects: 44
Study 31647267 — intervention group
Group type: EXPERIMENTAL
Intervention: DBT-skills group (DBT-S)
Number of subjects: 84
Study 31647267 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 84
Study 29794828 — intervention group
Group type: EXPERIMENTAL
Intervention: Bictegravir, emtricitabine, and tenofovir alafenamide (after switching from initial treatment)
Number of subjects: 0
Study 29794828 — intervention group
Group type: COMPARATOR
Intervention: Bictegravir or dolutegravir with emtricitabine and tenofovir alafenamide (initial treatment)
Number of subjects: 0
Study 27249205 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed eslicarbazepine acetate (800 mg)
Number of subjects: 28
Study 27249205 — intervention group
Group type: COMPARATOR
Intervention: Intact eslicarbazepine acetate (800 mg)
Number of subjects: 28
Study 24792798 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbial inoculant
Number of subjects: 3
Study 24792798 — intervention group
Group type: COMPARATOR
Intervention: Without microbial inoculant
Number of subjects: 3
Study 24792798 — intervention group
Group type: EXPERIMENTAL
Intervention: Regrowth intervals (35, 45, 55, 65 days)
Number of subjects: 3
Study 23300624 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 µg iloprost
Number of subjects: 16
Study 23300624 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 µg iloprost
Number of subjects: 16
Study 23300624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 20489176 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized long-term care at the stroke outpatient clinic
Number of subjects: 163
Study 20489176 — intervention group
Group type: COMPARATOR
Intervention: Usual care with general practitioner
Number of subjects: 163
Study 18547173 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection techniques that increase the dissection of the subepidermal plane (e.g., fanlike needle use, rapid injection, rapid flow rates, and higher volumes)
Number of subjects: 283
Study 18547173 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection techniques that increase epidermal damage or subcutaneous exposure (e.g., multiple punctures or deep subcutaneous injection)
Number of subjects: 283
Study 18547173 — intervention group
Group type: EXPERIMENTAL
Intervention: Single injection correction, depth of injection, and NASHA product injected
Number of subjects: 283
Study 16080579 — intervention group
Group type: COMPARATOR
Intervention: IL-2, 1.8 x 10(6) I.U. for 5 days/week for 2 consecutive cycles of 3 weeks, with a 1-week interval (arm A)
Number of subjects: 112
Study 16080579 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2, 1.8 x 10(6) I.U. for 5 days/week for 2 consecutive cycles of 3 weeks, with a 1-week interval plus oral RA, 0.5 mg/Kg (arm B)
Number of subjects: 112
Study 12593726 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Number of subjects: 225
Study 12593726 — intervention group
Group type: COMPARATOR
Intervention: No treatment (controls)
Number of subjects: 225
Study 12593726 — intervention group
Group type: EXPERIMENTAL
Intervention: Endogenously suppressed TSH follow-up group
Number of subjects: 225
Study 10559528 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/kg oral methionine
Number of subjects: 29
Study 8885917 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids after treatment with ampicillin-sulbactam
Number of subjects: 77
Study 8885917 — intervention group
Group type: COMPARATOR
Intervention: No corticosteroids (control group)
Number of subjects: 77
Study 1947617 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg ranitidine
Number of subjects: 51
Study 1947617 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 6833169 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent advice package with experimenter assistance
Number of subjects: 9
Study 6833169 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent advice package without experimenter assistance
Number of subjects: 9
Study 30916121 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5% maltodextrin (200 mL, 2 h before anesthesia)
Number of subjects: 57
Study 30916121 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative infusion of ω‐3 PUFA (0.2 g/kg)
Number of subjects: 57
Study 30916121 — intervention group
Group type: COMPARATOR
Intervention: Water (200 mL, 2 h before anesthesia) plus intraoperative infusion of ω‐3 PUFA (0.2 g/kg)
Number of subjects: 57
Study 30916121 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative infusion of ω‐3 PUFA
Number of subjects: 57
Study 30392002 — intervention group
Group type: EXPERIMENTAL
Intervention: PHP-SMA
Number of subjects: 19
Study 30392002 — intervention group
Group type: COMPARATOR
Intervention: Control (standard SMA)
Number of subjects: 19
Study 27032700 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential FOLFIRI followed by docetaxel/cisplatin
Number of subjects: 1072
Study 27032700 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil monotherapy
Number of subjects: 1072
Study 25599306 — intervention group
Group type: EXPERIMENTAL
Intervention: Biochemical and pain biomarkers analysis including VICM, CRP, CRPM, CIIIM, CIIM, CIM, WOMAC, Lequesne, and pain catastrophizing scores.
Number of subjects: 216
Study 25599306 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster analysis applied to the optimal variable subset from principal component analysis.
Number of subjects: 216
Study 25599306 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure pain thresholds, temporal summation to pressure stimuli, and conditioning pain modulation measurements.
Number of subjects: 216
Study 22289414 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental subtraction
Number of subjects: 9
Study 22289414 — intervention group
Group type: EXPERIMENTAL
Intervention: Word association
Number of subjects: 9
Study 22289414 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor imagery
Number of subjects: 9
Study 22289414 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental rotation
Number of subjects: 9
Study 22289414 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of brain-teasers and dynamic imagery tasks
Number of subjects: 9
Study 20336040 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of bacterial wound colonization and procalcitonin blood level > or =2 ng/ml
Number of subjects: 47
Study 18476417 — intervention group
Group type: EXPERIMENTAL
Intervention: Qishen Huoxue Granule (QHG) plus conventional Western medicine
Number of subjects: 167
Study 18476417 — intervention group
Group type: COMPARATOR
Intervention: Conventional Western medicine
Number of subjects: 167
Study 16498185 — intervention group
Group type: EXPERIMENTAL
Intervention: AirHeel (Aircast, Inc.)
Number of subjects: 50
Study 16498185 — intervention group
Group type: COMPARATOR
Intervention: 1st Step prefabricated foot insert (Wrymark, Inc)
Number of subjects: 50
Study 12460350 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lignocaine
Number of subjects: 121
Study 12460350 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 121
Study 12460350 — intervention group
Group type: COMPARATOR
Intervention: No injection
Number of subjects: 121
Study 10535397 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox 250 mg
Number of subjects: 12
Study 10535397 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8946978 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg
Number of subjects: 520
Study 8946978 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg
Number of subjects: 520
Study 8946978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 520
Study 1684750 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg (SOD)
Number of subjects: 12
Study 1684750 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine 20 mg (SOD)
Number of subjects: 12
Study 1684750 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine (SS)
Number of subjects: 12
Study 1684750 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine (SOD)
Number of subjects: 12
Study 1684750 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine (SOD)
Number of subjects: 12
Study 1684750 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6580840 — intervention group
Group type: EXPERIMENTAL
Intervention: Vindesine (VDS; 2 mg/m2 i.v., twice or once weekly) in combination with prednisolone (Pred; 40 mg/m2 p.o., daily)
Number of subjects: 100
Study 6580840 — intervention group
Group type: COMPARATOR
Intervention: Vincristine (VCR; 1.2 mg/m2 i.v., once weekly) in combination with prednisolone (Pred; 40 mg/m2 p.o., daily)
Number of subjects: 100
Study 31004075 — intervention group
Group type: EXPERIMENTAL
Intervention: galcanezumab 150 mg biweekly for 12 weeks
Number of subjects: 217
Study 31004075 — intervention group
Group type: COMPARATOR
Intervention: placebo biweekly for 12 weeks
Number of subjects: 217
Study 31004075 — intervention group
Group type: EXPERIMENTAL
Intervention: galcanezumab
Number of subjects: 217
Study 31004075 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 217
Study 29973207 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio + Video
Number of subjects: 15
Study 29973207 — intervention group
Group type: COMPARATOR
Intervention: Audio Only
Number of subjects: 15
Study 29973207 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Audio + Video vs. Audio Only
Number of subjects: 15
Study 26896964 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental refusal to participate in trials
Number of subjects: 92
Study 26896964 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific treatment arm rather than randomization
Number of subjects: 92
Study 25132119 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery (RYGB or SG)
Number of subjects: 40
Study 25132119 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline adiponectin level
Number of subjects: 40
Study 25132119 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated adiponectin
Number of subjects: 40
Study 22219517 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol (1, 1.5, or 2 g daily for 4 weeks)
Number of subjects: 10
Study 19794285 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate (100 mg every week) plus Calcium (500 mg daily) and Vitamin D3 (800 mg daily)
Number of subjects: 46
Study 19794285 — intervention group
Group type: COMPARATOR
Intervention: Supplements only (Calcium 500 mg daily and Vitamin D3 800 mg daily)
Number of subjects: 46
Study 17932438 — intervention group
Group type: EXPERIMENTAL
Intervention: MTCT prophylaxis (3 short course zidovudine (AZT), 19 single-dose nevirapine (NVP), 5 both AZT and NVP)
Number of subjects: 41
Study 17932438 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose NVP for infants
Number of subjects: 41
Study 17932438 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusively formula-fed infants
Number of subjects: 41
Study 17932438 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed fed infants
Number of subjects: 41
Study 17557989 — intervention group
Group type: EXPERIMENTAL
Intervention: High dairy consumption (3 portions of dairy each day)
Number of subjects: 58
Study 17557989 — intervention group
Group type: COMPARATOR
Intervention: Low dairy consumption (1 portion of dairy each day)
Number of subjects: 58
Study 14769077 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient image presented for 33 ms during reading
Number of subjects: 0
Study 14769077 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual events with varying saliency
Number of subjects: 0
Study 14769077 — intervention group
Group type: COMPARATOR
Intervention: Abrupt auditory stimuli
Number of subjects: 0
Study 14769077 — intervention group
Group type: EXPERIMENTAL
Intervention: Display changes inside or outside the perceptual span
Number of subjects: 0
Study 14769077 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive or attentional modulation
Number of subjects: 0
Study 10944139 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk index score >/= 21
Number of subjects: 756
Study 10944139 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive factors for low risk
Number of subjects: 756
Study 9428114 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoral
Number of subjects: 38
Study 9428114 — intervention group
Group type: COMPARATOR
Intervention: Sandimmun
Number of subjects: 38
Study 8156864 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial Coordinator activities including recruitment, screening, medical management, education and training, adherence and administration
Number of subjects: 21
Study 2427851 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol 200 mg
Number of subjects: 12
Study 2427851 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol 400 mg
Number of subjects: 12
Study 2427851 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2427851 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 12
Study 31974935 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixated but irrelevant center item sharing features of the target item
Number of subjects: 0
Study 31974935 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased sample sizes in Experiments 4 and 5
Number of subjects: 0
Study 31974935 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear search layout
Number of subjects: 0
Study 31974935 — intervention group
Group type: EXPERIMENTAL
Intervention: Circular search layout
Number of subjects: 0
Study 30511316 — intervention group
Group type: EXPERIMENTAL
Intervention: GB242
Number of subjects: 48
Study 30511316 — intervention group
Group type: COMPARATOR
Intervention: Reference Infliximab
Number of subjects: 48
Study 28132762 — intervention group
Group type: EXPERIMENTAL
Intervention: Developed equations based on combinations of six to nine anthropometric variables.
Number of subjects: 601
Study 28132762 — intervention group
Group type: COMPARATOR
Intervention: Previously published equations (e.g., Slaughter).
Number of subjects: 601
Study 25569396 — intervention group
Group type: EXPERIMENTAL
Intervention: Open surgery
Number of subjects: 32
Study 25569396 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic surgery
Number of subjects: 32
Study 25569396 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 32
Study 23866738 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week yoga programme (1 class per week)
Number of subjects: 100
Study 23866738 — intervention group
Group type: COMPARATOR
Intervention: Control group (no yoga intervention)
Number of subjects: 100
Study 21074006 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxious group (Experiment 1)
Number of subjects: 150
Study 21074006 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxious group (Experiment 2)
Number of subjects: 150
Study 21074006 — intervention group
Group type: COMPARATOR
Intervention: Neutral group (Experiment 2)
Number of subjects: 150
Study 21074006 — intervention group
Group type: COMPARATOR
Intervention: Happy group (Experiment 2)
Number of subjects: 150
Study 19894388 — intervention group
Group type: EXPERIMENTAL
Intervention: XIAs No. 1 Sleeping Prescription
Number of subjects: 120
Study 19894388 — intervention group
Group type: COMPARATOR
Intervention: Estazolam (1 mg) for 6 weeks
Number of subjects: 120
Study 19894388 — intervention group
Group type: COMPARATOR
Intervention: Adverse reactions
Number of subjects: 120
Study 17129304 — intervention group
Group type: EXPERIMENTAL
Intervention: Subhepatic administration of 20 mL of 0.5% bupivacaine just after the creation of pneumoperitoneum (group 2)
Number of subjects: 80
Study 17129304 — intervention group
Group type: COMPARATOR
Intervention: Subhepatic administration of 20 mL of 0.5% bupivacaine before pneumoperitoneum (group 1)
Number of subjects: 80
Study 17129304 — intervention group
Group type: COMPARATOR
Intervention: Subhepatic administration of 20 mL of 0.5% bupivacaine just before removal of the trocars (group 3)
Number of subjects: 80
Study 17129304 — intervention group
Group type: COMPARATOR
Intervention: No local anesthetic (group 4)
Number of subjects: 80
Study 15126514 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modification aimed at weight loss (changes in diet and increased physical exercise)
Number of subjects: 490